The European Medicines Agency (EMA) has reported the establishment of a new supply chain to address the shortage of 'Visudyne' (verteporfin), a medicine used for injection against serious eye conditions such as age-related macular degeneration in its moist form and choroid neovascularization caused by pathological myopia.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.
The European Medicines Agency (EMA) has reported the establishment of a new supply chain to address the shortage of 'Visudyne' (verteporfin), a medicine used for injection against serious eye conditions such as age-related macular degeneration in its moist form and choroid neovascularization caused by pathological myopia.